A further bispecific, humanized IgG1 antibody which is less than investigation is zenocutuzumab (MCLA-128), which acts by way of two impartial mechanisms of action: inhibition of HER2–HER3 signalling and elimination of tumour cells by way of ADCC. MCLA-128 features through a ‘dock and block’ mechanism whereby 1 arm from the https://www.directivepublications.org/journal-of-clinical-breast-cancer/